Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as the company phases out…
Trending
- India’s economy projected to grow by 6.5% in FY26: EY
- Will high gold prices dampen Akshay Tritiya? What are jewellers doing to boost sales
- Reliance Industries Q4 results: Net profit rises 2.4% to Rs 19,407 crore in March quarter
- US markets open flat after 3 day gain amid looming trade tensions
- Push for ‘Make in India’: Samsung to invest Rs 1,000 crore in Chennai facility
- India’s forex reserves rise for seventh straight week, jumps $8.31 billion to $686 billion
- Indian aviation sector continues to face disruptions in supply chain: ICRA report | India-Business News
- India’s GDP growth outlook trimmed to 6.3% as private investment stalls and US tariffs loom: Report
- RBI’s gold buying spree continues! 57.5 tonnes added to gold reserves; second highest in 7 years
- China’s snub to India’s advantage? Air India in talks to buy 10 Boeing planes rejected by Chinese airlines amid Sino-US tariff war
